The Food and Drug Administration is investigating a link between the asthma drug Singulair and suicidal behavior, according to a news release Thursday.

 

The FDA has requested Singulair's manufacturer Merck & Co. evaluate the drug's data for more information about suicidality and mood changes, according to the news release.

The agency is also reviewing the post-marketing reports of patients who have reported such behavior after taking the drug.